When is infliximab indicated in the management of Crohn disease?

Updated: Jul 26, 2019
  • Author: Leyla J Ghazi, MD; Chief Editor: Praveen K Roy, MD, AGAF  more...
  • Print

Infliximab is effective in patients who have refractory perianal and enterocutaneous fistulae. Current clinical practice is to give it 5 mg/kg by intravenous (IV) infusion at 0 weeks, 2 weeks, and 6 weeks, followed by maintenance IV infusions every 8 weeks. On average, the effect lasts for 12 weeks.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!